PTO/SB/08a/b (07-06)
Approved for use through 09/30/2006. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substi	ute for form 1449A/B	VPTO	,	Complete if Known		
3005111	ute 101 101111 144570	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		Application Number	10/764,140-Conf. #6085	
INF	ORMATIC	ON DISC	LOSURE	Filing Date	January 22, 2004	
	ATEMENT			First Named Inventor	Jin-An Jiao	
•				Art Unit	1647	
(Use as many sheets as necessary)				Examiner Name	C. M. Borgeest	
Sheet	1	of	9	Attorney Docket Number	TNA-00505	

U.S. PATENT DOCUMENTS								
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant			
Initials*	No.¹	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Figures Appear			
CQ	AA*	US-20020025508-A1	02-28-2002	Fechteler et al.				
ĺ	AB*	US-20030087372-A1	05-08-2003	DelaCruz et al.				
	AC*	US-20030119075-A1	03-09-2004	Kirchhofer et al.				
	AD*	US-20040229282-A1	11-18-2004	Wong et al.				
	AE*	US-4,644,055	02-17-1987	Kettner et al.				
	AF*	US-4,816,567	03-28-1989	Cabilly et al.				
	AG*	US-5,122,458	06-16-1992	Post et al.				
	AH*	US-5,168,062	12-01-1992	Stinski				
	AI*	US-5,171,662	12-15-1992	Sharma				
	AJ*	US-5,225,539	07-06-1993	Winter et al.				
	AK*	US-5,385,839	01-31-1995	Stinski				
	AL*	US-5,530,101	06-25-1996	Queen et al.				
	AM*	US-5,534,254	07/1996	Huston et al.				
	AN*	US-5,766,886	06-16-1998	Studnicka et al.				
	AO*	US-5,861,267	01-19-1999	Su				
	AP*	US-5,879,677	03-09-1999	del Zoppo				
	AQ*	US-5,889,157	03-30-1999	Pastan et al.				
	AR*	US-5,958,713	09-28-1999	Thastrup et al.				
	AS*	US-5,985,279	11-16-1999	Waldmann et al.				
	AT*	US-5,997,867	12-07-1999	Waldmann et al.				
1	AU*	US-6,001,978	12-14-1999	Edgington et al.				
	AV*	US-6,054,297	04-25-2000	Carter et al.				
	AW*	US-6,117,639	09-12-2000	Germann et al.				
	AX*	US-6,245,884	06-12-2001	Hook				
	AY*	US-6,309,636	10-30-2001	do Couto et al.				
1	AZ*	US-6,331,415	12-18-2001	Cabilly et al.				
	AA1*	US-6,333,167	12-25-2001	Quinet et al.				
		US-6,555,319-A1	04-29-2003	Wong et al.				
	AC1*	US-6,593,291	07-15-2003	Green et al.				
\neg		US-6,610,293		Fischer et al.				
-V		US-6,677,436	01-13-2004	Sato et al.				
CB	AF1°		03-09-2004	Kirchhofer et al.				

FOREIGN PATENT DOCUMENTS										
Examiner	Cite	Foreign Patent Document Publication		Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	76				
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	1				
CB	ВА	WO 91/18019	11-28-1991							
	ВВ	WO 96/13593	05-06-1996			L_				
	ВС	WO 96/18105 ·	06-13-1996			L				
	BD	EP 0 420 937	10/1991							
	ВІ	JP-1-503438	02/1989			<u> </u>				
	BA1	EP 1 069 185	01-17-2001			_				
1	BB1	WO 89/12463 ·	12-28-1989			L.				
CB	BC1	WO 03/029295	04-10-2003	-		<u></u>				

Examiner Signature Christian Borocest	Date Considered	3/1/2007
		•

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substit	ute for form 1449A/B	PTO		Complete if Known		
Jubani	ate for form 1445% of			Application Number	10/764,140-Conf. #6085	
INF	ORMATIC	N DI	SCLOSURE	Filing Date	January 22, 2004	
STATEMENT BY APPLICANT				First Named Inventor	Jin-An Jiao	
				Art Unit	1647	
(Use as many sheets as necessary)				Examiner Name	C. M. Borgeest	
heet	2	of	9	Attorney Docket Number	TNA-00505	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was fited after June 30, 2003 or is available in the IFW. 'Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
CB	AA1	Alberts et al., "The Cell, 2002, Garland Science, 4th Edition, pp. 161, Fig. 3-42	<u> </u>
as	AB1	Benhar et al., "Rapid Humanization of the Fv of Monoclonal Antibody B3 by Using Framework Exchange of the Recombinant Immunotoxin B3(Fv)-PE38," Proc. Natl. Acad. Sci. USA, 91:12051-12055 (1994)	
CM	AC1	Boulianne et al., "Production of functional chimaeric mouse/human antibody," Nature, 312:643-646 (1984)	
CB	AD1	Bruggemann et al., "The Immunogenicity of Chimeric Antibodies," J. Exp. Med. 170:2153-2157 (1989)	
Cs	AE1	Cacia et al., "Isomerization of an Aspartic Acid Residue in the Complementarity-Determining Regions of a Recombinant Antibody to Human IgE: Identification and Effect on Binding Affinity," Biochemistry, 35:1897-1903 (1996)	
CB	AF1	Carter et al., "Humanization of an anti-p185HER2 antibody for human cancer therapy," Proc. Natl. Acad. Sci. USA, 89:4285-4289 (1992)	
CB	AG1	Casipit et al., "Improving the binding affinity of an antibody using molecular modeling and site directed mutagenesis." Protein Science, 7:1671-1680 (1998)	
OB	AH1	Co et al., "Humanized antibodies for antiviral therapy," Proc. Natl. Acad. Sci. USA, 88:2869-2873 (1991)	
03	Al1	Couto et al., "Anti-BA46 Monoclonal Antibody Mc3: Humanization Using a Novel Positional Consensus and In Vivo and In Vitro Characterization," Cancer Research, 55:1717-1722 (1995)	
cos	AJ1	Couto et al., "Designing Human Consensus Antibodies with Minimal Positional Templates," Cancer Research (Suppl.) 55:5973s-5977s (1995)	
ca	AK1	Faber et al., "A Novel Method to Determine the Topology of Peroxisomal Membrane Proteins in Vivo Using the Tobacco Etch Virus Protease," The Journal of Biological Chemistry, 276(39):36501-36507 (2001)	
CB	AL1	Foote et al., "Antibody Framework Residues Affecting the Conformation of the Hypervariable Lopes" J. Mol. Biol., 224:487-499 (1992)	
crs	AM1	Gorman et al., "Reshaping a therapeutic CD4 Antibody," Proc. Natl. Acad. Sci. USA, 88:4181-4185 (1991)	
CB	AN1	Griffiths et al., "Human anti-self antibodies with high specificity from phage display libraries," The EMBO Journal, 12(2):725-734 (1993)	
CB	AO1	Hanes et al., "Picomolar affinity antibodies from a fully synthetic naïve library selected and evolved by ribosome display," Nature Biotechnology, 18:1287-1292 (2000)	
CB	AP1	Jager et al., "Current Status of Cancer Immunodetection with Radiolabeled Human Monoclonal Antibodies," Seminars in Nuclear Medicine, Vol. XXIII, No. 2, 165-179 (1993)	
CB	AQ1	Janeway et al., Immunobiology, third edition, Garland Press, pp. 3:7-3:11 (1997)	<u> </u>
CB	AR1	Kao et al., "Chimeric Antibodies with Anti-Dextran-Derived Complementarity-Determining Regions and Anti-p-Azophenylarsonate-Derived Framework Regions," The Journal of Immumology, 151:1968-1979 (1993)	

Examiner Signature Christina Boracust	Date Considered 3/107	
	• •	

PTO/SB/08a/b (07-06)
Approved for use through 09/30/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sut	Substitute for form 1449A/B/PTO			Complete if Known		
	The second secon	•		Application Number	10/764,140-Conf. #6085	
11	NFORMATION	I DI	SCLOSURE	Filing Date	January 22, 2004	
S	TATEMENT E	3Y A	APPLICANT	First Named Inventor	Jin-An Jiao	
Ŭ				Art Unit	1647	
	(Use as many she	ets as	necess ary)	Examiner Name	C. M. Borgeest	
Sheet	3	of	9	Attorney Docket Number	TNA-00505	

		1	1 1 1 1 1 1	1.041))						
00	AS1	Knappik et al., "Fully Synthetic Human Combinatorial Antib Modular Consensus Frameworks and CDRs Randomized v								
CB	<u> </u>	296:57-86 (2000)								
CB	AT1	Leong et al., "Adapting pharmacokinetic properties of a hur for therapeutic applications using site-specific pegylation,"	Cytokine, 16(3)	:106-119 (2001)						
B	AU1	LoBuglio et al., "Mouse/human chimeric monoclonal antibo response," Proc. Natl. Acad. Sci. USA, 86:4220-4224 (198		etics and immune						
CB	AV1	Mateo et al., "Humanization of a mouse monoclonal antibo- factor receptor: recovery of antagonistic activity," Immunote	dy that blocks t							
CB	AW1	Morrison et al., "Chimeric human antibody molecules: Mou	Morrison et al., "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains," Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)							
CB	AX1	Morrison et al., "Genetically Engineered Antibody Molecules," Advances in Immunology, 44:65-93								
	AY1	Owens et al., "The Generic Engineering of Monoclonal Ant Methods, 168:149-165 (1994)	ibodies," Journ	at of Immunological						
CB	AZ1	Padlan, "A possible procedure for reducing the immunoger while preserving their ligand-binding properties," Mol. Immunoger								
CB	AA2	Padlan, "Anatomy of the antibody molecule," Molecular Imi	nunology 31(3):169-217 (1994)						
<u>us</u>	AB2	Padlan, "On the Nature of Antibody Combining Sites: Unus	ual Structural F	eatures That May						
CB	AUZ	Confer on These Sites an Enhanced Capacity for Binding L (1990)	igands," Prote	ins, 7:112-124						
<u> </u>	AC2	Ougan et al. "A humanized antibody that hinds to the inter	leukin 2 recent	or " Proc. Natl. Acad.						
co		Queen et al., "A humanized antibody that binds to the interleukin 2 receptor," Proc. Natl. Acad. Sci. USA, 86:10029-10033 (1989)								
CB	AD2	Queen et al., "Cell-Type Specific Regulation of a k Immunoglobin Gene by Promoter and Enhancer Elements," Immunological Reviews, 89:49-68 (1986)								
CB	AE2	Reichart, "Monoclonal antibodies in the clinic," Nature Biotechnology, 19:819-822 (2001)								
CB	AF2	Reichmann et al., "Reshaping human antibodies for therapy," Nature, 332:323-327 (1988)								
CB	AG2	Robertson, "Genentech awarded critical antibody patent," (2002)								
CB	AH2	Roguska et al., "A comparison of two murine monoclonal a grafting and variable domain resurfacing," Protein Enginee	ring, 9(10):895	-904 (1996)						
CB	Al2	Roguska et al., "Humanization of murine monoclonal antiboresurfacing," Proc. Natl. Acad. Sci. USA, 91:969-973 (1994)	ł)							
CB	AJ2	Rudikoff et al., "Single amino acid substitution altering antiq Acad. Sci. USA, 79:1979-1983 (1982)	gen-binding sp	ecificity," Proc. Natal.						
	AK2	Saldanha et al., "A single backmutation in the human kIV fi	ramework of a	previously						
CB CB		unsuccessfully humanized antibody restores the binding accos cells," Molecular Immunology, 36:709-719 (1999)	ctivity and incre	ases the secretion in						
	AL2	Shearman et al., "Construction, expression and characterize	ation of humar	nized antibodies						
CB		directed against the human α/β T cell receptor," The Journal (1991)	al of Immunolo	gy, 147:4366-4373						
	AM2	Tan et al., "Superhumanized Antibodies: Reduction of Imm Complementarity-Determining Region Grafting with Human	i Germline Seq	ntial by uences: Application						
CB_		to an Anti-CD28," The Journal of Immunology, 169:1119-1	125 (2002)							
CB	AN2	Tempest et al., "Reshaping a human monoclonal antibody syncytial virus infection in vivo," Bio/Technology, 9:266-27	1 (1991)							
CB	AO2	Teng et al., "Construction and testing of mouse-human het antibody production," Proc. Natl., Acad. Sci. USA, 80:7308	ermyelomas fo -7312 (1983)							
	AP2	Tornizuka et al., "Double trans-chromosomic mice: Mainter	nance of two in	dividual human						
CB		chromosome fragments containing Ig heavy and k lock and antibodies," PNAS, 97(2):722-727 (2000)	expression of	fully human						
Evenies	' 	4	Date							
Examine: Signature		Christia Boracest	Considered	3/1/07						
3.3.10.010		/ · · · · · · · · · · · · · · · · · · ·								

	Under the Paperwork Redu	ıction Act	of 1995, no persons are require	U.S. Patent and Traden	PTO/SB/08a/b (07-06) wed for use through 09/30/2006. OMB 0651-0031 nark Office; U.S. DEPARTMENT OF COMMERCE ormation unless it contains a valid OMB control number.
Sut	stitute for form 1449A/B/F	TO			Complete if Known
300	stitute for form 1449201	.0		Application Number	10/764,140-Conf. #6085
IN	IFORMATIO	N DI	SCLOSURE	Filing Date	January 22, 2004
	TATEMENT			First Named Inventor	Jin-An Jiao
	.,,,			Art Unit	1647
	(Use as many s	he ets as	necessary)	Examiner Name	C. M. Borgeest
Sheet	4	of	9	Attorney Docket Number	TNA-00505

	,								
/_	AQ2	Vaughan et al., "Human Antibodies with Sub-nanomolar Af							
CB	1.00	immunized Phage Display Library," Nature Biotechnology,	14.305-314 (18	o Activity " Science					
OB	AR2	Verhoeyen et al., "Reshaping Human Antibodies: Grafting 239:1534-1536 (1988)	an Antilysozym	e Activity, Science,					
	AS2	Watson et al., Molecular Biology of the Gene, fourth edition	n, The Benjamii	n/Cummings					
CB	ļ	Publishing Company, Inc., p. 840 (1987)							
IDF Albrecht et al. "An ELISA for tissue factor using monoclonal antibodies." Blood Coagula									
Cos	3 and Fibrinolysis, 3:263-270 (1992)								
İ	DG	DG Almus et al., "Properties of Factor VIIa/Tissue Factor Complexes in an Umbilical Vein Model,"							
Cs	<u> </u>	Blood, 76(2):354-360 (1990)							
	DH	Ardaillou et al., "Glomerular tissue factor stimulates thromb		is in human platelets					
Cas		via thrombin generation," Kidney International, 41:361-368	(1992)						
	DI	Barstad et al., "Procoagulant Human Monocytes Mediate T	issue Factor/F	actor VIIa-Dependent					
ra	1	Platelet-Thrombus Formation When Exposed to Flowing N		ed Human Blood,"					
CB	l	Arterioslerosis, Thrombosis, and Vascular Biology, 15(1):1	1-16 (1995)						
	DJ	Beers et al., The Merck Manual of Diagnosis and Therapy,	17th edition, 1	999, Merck					
CA		Research Laboratories, pps. 1654-1681							
	DK	Benedict et al., "Monoclonal Antibody to Tissue Factor Inhi	bits Intravascul	ar Thrombosis					
	1	without Imparing Extravascular Hemostasis," JACC, Febru	ary 1995 Abstr	act 1012-104, p.					
CB	<u> </u>	366A							
	DL	Bjoern et al., "Human Plasma and Recombinant Factor VII	," The Journal	of Biological					
<u>U3</u>	<u> </u>	Chemistry, 266(17):11051-11057 (1991)							
CB CB	DM	Broze, George J., Jr., "Binding of Human Factor VII and VI	la to Monocyte	s," J. Clin. Invest.					
CB		The American Society for Clinical Investigation, Inc., 70:52	6-535 (1982)						
	DN	Carson et al., "An Inhibitory Monoclonal Antibody Against I	Human Tissue	Factor," Blood,					
CB		70(2):490-493 (1987)							
	DO	Carson et al., "Monoclonal Antibodies Against Bovine Tisse	ue Factor, Whic	ch Block Interaction					
CB	L	With Factor VII," Blood, 66(1):152-156 (1985)							
CB CB	DP	Cate et al., "The Activation of Factor X and Prothrombin by	Recombinant	Factor VIIa in Vivo Is					
\mathcal{O}	<u> </u>	Mediated by Tissue Factor," The Journal of Clinical Investi	gation, Inc., 92	1207-1212 (1993)					
١,,	DQ	Chapman et al., "Regulation of the Procoagulant Activity w	ithin the Bronc	hoalveolar					
UB_		Compartment of Normal Human Lung," Am. Rev. Respir. D	Dis., 13/(6):141	7-1425 (1988)					
0-	DR	Chattopadhyay et al., "Molecular Recognition Sites on Fac	tor Xa Which P	rarticipate in the					
CB	ļ	Prothrombinase Complex," The Journal of Biological Chem							
	DS	Clarke et al., "The first epidermal growth factor domain of h							
00		essential for binding with tissue factor," Federation of Euro	pean Biochemi	cai Societies,					
CB	<u> </u>	298(2,3):206-310 (1992)	mr t- Or -t						
00	DT	Collen et al., "New thrombolytic agents and strategies," Ba	illiere's Clinical	naematology,					
CB	 	8(2):425-435 (1995)		aga interactions "					
	DÜ	Colman, P.M., "Effects of amino acid sequence changes o	n antibody-anti	gen interactions,					
OB	 	Research in Immunology, 145:33-36 (1994)	unational Ties:	in Easter Expression					
	Dν	Contrino et al., "In Situ Characterization of Antigenic and F	unctional risst	or VIII of Probos "					
Cos	1	in Human Tumors Utilizing Monoclonal Antibodies and Red	combinant ract	or vita as Floues,					
	1000	Americal Journal of Pathology, 145(6):1315-1322 (1994)	ago Evarage	00					
	DW	Drake et al., "Functional Tissue Factor Is Entirely Cell Surf	ace Expressed	volv Tissua Factor					
Crs		Lipopolysaccharide-stimulated Human Blood Monocytes a	no a Constitutiv	VEIY 1155UE PACIOI-					
45	·	producing Neoplastic Cell Line," The Journal of Cell Biolog	y, 109.309-395	(1303)					
01	DX	Drake et al., "Selective Cellular Expression of Tissue Factor	or in mujinan Tis	Sues, Amendan					
CB		Journal of Pathology, 134(5):1087-1097 (1989) Fair et al., Cooperative Interaction Between Factor VII and	Call Surface E	vorgeed Tiesus					
CB	DY	Factor, The Journal of Biological Chemistry, Vol. 262, Aug	UCH 3011408-E	n 11692-11698					
		ractor, the Journal of Biological Chemistry, Vol. 262, Aug		p. 11032-11030					
Examine		1 11 Barret	Date	3/1/2007					
Signature	<u> </u>	hristia-Borgeest	Considered	<u> </u>					

PTO/SB/08a/b (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sul	bstitute for form 1449A/B/	PTO		Complete if Known		
-		•		Application Number	10/764,140-Conf. #6085	
11	NFORMATIO	N DI	SCLOSURE	Filing Date	January 22, 2004	
S	TATEMENT	BY A	APPLICANT	First Named Inventor	Jin-An Jiao	
				Art Unit	1647	
	(Use as many s	she ets as	necess ary)	Examiner Name	C. M. Borgeest	
Sheet	5	of	9	Attorney Docket Number	TNA-00505	

	ΟZ	Faulk et al., "Tissue Factor: Identification and Characterization of Cell Types in Human Placentae," Blood, 76(1):86-96 (1990)					
E	EA	Fay et al., "Mutating factor VIII: lessons from structure to function," Blood Reviews, 19:15-17 (2005)					
	EB	Flössel et al., "Immunohistochemical detection of tissue factor (TF) on paraffin sections of routinely fixed human tissue," Histochemistry, 101:449-453 (1994)					
	EÇ	Gouault-Heilmann et al., "The Procoagulant Factor of Leukaemic Promyelocytes: Demonstration of Immunologic Cross Reactivity with Human Brain Tissue Factor," British Journal of Haematology, 30:151-158 (1975)					
E	ED	Grabowski et al., "The Functional Expression of Tissue Factor by Fibroblasts and Endothelial Cells Under Flow Conditions," Blood, 81(2):3265-3270 (1993)					
E	EE	Hamaguchi et al., "FDP D-Dimer Induces the Secretion of Interleukin-1, Urokinase-Type Plasminogen Activator, and Plasminogen Activator Inhibitor-2 in a Human Promonocytic Leukemia Cell Line," Blood, 77(1):94-100 (1991)					
E	EF	Hoffman et al., "Human Monocytes Support Factor X Activation by Factor VIIa, Independent of Tissue Factor: Implications for the Therapeutic Mechanism of High-Dose Factor VIIa in Hemophilia," Blood, 83(1):38-42 (1994)					
8	EG	Huang et al., "The Mechanism of an Inhibitory Antibody on TF-initiated Blood Coagulation Revealed by the Crystal Structures of Human Tissue Factor, Fab 5G9 and TF 5G9 Complex," J. Mol. Biol., 275:873-894 (1998)					
E	EH	Imamura et al., "Role of Macrophage Tissue Factor in the Development of the Delayed Hypersensitivity Reaction in Monkey Skin," Cellular Immunology, 152:614-622 (1993)					
E	ÉÏ	Ito et al., "Characterization of Functionally Important Regions of Tissue Factor by Using Monoclonal Antibodies," J. Biochem., 114(5):691-696 (1993)					
E	ĒJ	James et al., "Inhibition of tissue factor activity reduces the density of cellular network formation in an in vitro model of angiogensis," Biochemical Society Transactions, 30(2):217-221 (2002)					
. [6	EK	Jang et al., "Antithrombotic Effect of a Monoclonal Antibody Against Tissue Factor in a Rabbit Model of Platelet-Mediated Arterial Thrombosis," Arteriosclerosis and Thrombosis, 12(8):948-954 (1992)					
E	EL	Kirchhofer et al., "The Tissue Factor Region That Interacts with Factor Xa in the Activation of Factor VII," Biochemistry, 40:675-682 (2001)					
E	EM	Kumar et al., "Identification of Molecular Sites on Factor VII Which Mediate Its Assembly and Function in the Extrinsic Pathway Activation Complex," The Journal of Biological Chemistry, 266(2):915-921 (1991)					
E	EN	Kumar et al., "Specific molecular interaction sites on factor VII involved in factor X activation," Eur. J. Biochem. 217:509-518 (1993)					
•	EO	Levi et al., "Inhibition of Endotoxin-induced Activation of Coagulation and Fibrinolysis by Pentoxifylline or by a Monoclonal Anti-tissue factor Antibody in Chimpanzees," The Journal of Clinical Investigation, Inc., 93:114-120 (1994)					
E	ΕP	Maekawa et al., "Complement-Dependent Immunosuppressive Anti-Tissue Factor Monoclonal Antibody: The Establishment of Monoclonal Antibodies and Their Effect on Mixed Lymphocyte Reaction," Transplantation Proceedings, 25(4):2713-2715 (1993)					
E	EQ	Martin et al., Activation of Factor X by Factor VIIa on Monocyte Cell Surfaces, pp. 3828 - 3829 Blood. 1994 Jun 15;83(12):3828-9.					
E	ER	Martin et al., "Tissue Factor: molecular recognition and cofactor function," The FASEB Journal, 9:852-859 (1995)					
. E	ES	Masuda et al., "Association of tissue factor with a γ chain homodimer of the IgE receptor type I in cultured human monocytes," Eur. J. Immunol., 26:2529-2532 (1996)					
E	ĒΤ	McGee et al., "Functional Difference between Intrinsic and Extrinsic Coagulation Pathways," The Journal of Biological Chemistry, 266(13):8079-8085 (1991)					
Examiner Signature		Date Considered					

PTO/SB/08a/b (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE respond to a collection of information unless it contains a valid OMB control number.

Substi	Substitute for form 1449A/B/PTO			Complete If Known		
00030	indication forms 1440740	.,, 10		Application Number	10/764,140-Conf. #6085	
INI	FORMATIO	ON DIS	SCLOSURE	Filing Date	January 22, 2004	
ST	ATEMEN	r by A	PPLICANT	First Named Inventor	Jin-An Jiao	
•	,,,,			Art Unit	1647	
	(Use as many	sheets as	necess ary)	Examiner Name	C. M. Borgeest	
Sheet	6	of	9	Attorney Docket Number	TNA-00505	

	EU	Merriam-Webster Online dictionary, downloaded October 11, 2005, world wide web at m-	
Co		w.com, definition of thrombosis, 2 pages	
CB	EV	Morrissey et al., "Monoclonal Antibody Analysis of Purified and Cell-Associated Tissue Factor," Thrombosis Research, 52:247-261 (1988)	
CB	EW	Morrissey et al., "Resolution of Monomeric and Heterodimeric Forms of Tissue Factor, the High-Affinity Cellular Receptor for Factor VII," Thrombosis Research, 50:481-493 (1988)	
010	EX	Mueller, Barbara M., Expression of Tissue Factor by Melanoma Cells Promotes Efficient	
(B		Hematogenous Metastasis, Proc. Natl. Acad. Sci. USA, December 1992, Vol. 89, pp. 11832-11836	
CB	EY	Muller et al., "Structure of the Extracellular Domain of Human Tissue Factor: Location of the Factor VIIa Binding Site," American Chemical Society, (1994)	
	EZ	Nemerson et al., "An Ordered Addition, Essential Activation Model of the Tissue Factor Pathway of Coagulation: Evidence for a Conformational Cage," Biochemistry, 25:4020-4033 (1986)	
CB CB	FA	Noguchi et al., "Correlation Between Antigenic and Functional Expression of Tissue Factor on the Surface of Cultured Human Endothelial Cells Following Stimulation by Lipopolysaccharide Endotoxin." Thrombosis Research, 55:87-97 (1989)	
ŀ	FB	Østerud et al., "The Interaction of Human Blood Coagulation Factor VII and Tissue Factor: The Effect of Anti Factor VII, Anti Tissue Factor and Diisopropylfluorophosphate." Biochemical and	
Cas	<u> </u>	Biophysical Research Communications, 88(1):59-67 (1979)	
_	FC	Pawashe et al., A Monoclonal Antibody Against Rabbit Tissue Factor Inhibits Thrombus	
CB	_	Formation in Stenotic Injured Rabbit Carotid Arteries, Tissue Factor and Intravascular Thrombosis, January 1994, Vol. 74, No. 1, pp. 56-63	
	FD	Ploplis et al., Initiation of the Extrinsic Pathway of Coagulation - Association of Factor VIIa with a Cell Line Expressing Tissue Factor, The Journal of Biological Chemistry, July 15, 1987, Vol.	
CB		262, pp. 9503-9508	
CB	FE	Price et al., "Tissue factor and tissue factor pathway inhibitor," Anaesthesia, 59:483-492 (2004)	
GR	EF	Rehemtulla et al., The Integrity of the Cysteine 186-Cysteine 209 Bond of the Second Disulfide Loop of Tissue Factor Is Required for Binding of Factor VII, The Journal of Biological	
UP	ļ	Chemistry, June 5, 1991, Vol. 266, No. 16, pp. 10294-10299	
CB	EG	Ruf et al., "An Anti-Tissue Factor Monoclonal Antibody Which Inhibits TF-VIIa Complex Is a Potent Anticoagulant in Plasma, Thrombosis and Haemostasis," F.K. Schattauer Verlagsgesellschaft mbH (Stuttgart) 66 (5) 529-533 (1991)	
_	EH	Ruf et al., "Antibody Mapping of Tissue Factor Implicates Two Different Exon-Encoded Regions in Function," Biochem J. (1991) 278, pp. 729-733	
d3	EI	Ruf et al "Characterization of Factor VII Association with Tissue Factor in Solution - High and	
		Low Affinity Calcium Binding Sites in Factor VII Contribute to Functionally Distinct	
CB		Interactions," The Journal of Biological Chemistry, Vol. 266, August 25, 1991, pp. 15719-15725	
CB	EJ	Ruf et al., "Phospholipid-independent and -dependent Interactions Required for Tissue Factor Receptor and Cofactor Function," The Journal of Biological Chemistry, February 5, 1991, Vol. 266, pp. 2158-2166	
CB	EK	Ruf et al., "Structural Biology of Tissue Factor, the Initiator of Thrombogenesis in Vivo," The	
1	EL	Ruf et al. "Tissue Factor Residues 157-167 Are Required for Efficient Proteolytic Activation of	
CB		Factor X and Factor VII," The Journal of Biological Chemistry, November 5, 1992, Vol. 267, No. 31, pp. 22206-22210	
CB	EM	Ruf et al., "Two Sites in the Tissue Factor Extracellular Domain Mediate the Recognition of the	
LUZ	<u> </u>	Ligand Factor VIIa," Proc. Natl. Acad. Sci. USA, October 1991, Vol. 88, pp. 8430-8434	

Examiner Signature Christina Borgest	Date Considered 3/1/07

PTO/SB/08a/b (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sul	ostitute for form 1449A/B/PT	·0		Complete if Known		
301	Salitate for form 14407407.	•		Application Number	10/764,140-Conf. #6085	
11	NFORMATION	I DI	SCLOSURE	Filing Date	January 22, 2004	
S	TATEMENT I	3Y /	APPLICANT	First Named Inventor Jin-An Jiao		
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			Art Unit	1647	
	(Use as many she	eets as	s necessary)	Examiner Name	C. M. Borgeest	
Sheet	7	of	9	Attorney Docket Number	TNA-00505	

	1=11	10
	EN	Ryan et al., "Tumor Necrosis Factor-Induced Endothelial Tissue Factor Is Associated With
	1	Subendothelial Matrix Vesicles But Is Not Expressed on the Apical Surface," Blood, August 15,
03	ļ	1992, Vol. 80, No. 4, pp. 966-974
1	EO	Sakai et al., "Binding of Human Factors VII and VIIa to a Human Bladder Carcinoma Cell Line
10	İ	(J82) - Implications For The Initiation of the Extrinsic Pathway of Blooad Coagulation," The
CB	1	Journal of Biological Chemistry, Vol. 264, No. 17, June 15, 1989, pp. 9980-9988
	EP	Salatti et al., "Modulation of Procoagulant Activity of Extracellular Endothelial Matrix by Anti-
l	1	Tissue Factor Antibody and the Synthetic Peptide Arg-Gly-Asp-Val. Experiments with Flowing
		Non-Anticoagulated Human Blood," Blood Coagulation and Fibrinolysis, 1993, Vol. 4, pp. 881-
CB	1	890
	EQ	Sandset et al., "Immunodepletion of Extrinsic Pathway Inhibitor Sensitizes Rabbits to
		Endotoxin-Induced Intravascular Coagulation and the Generalized Shwartzman Reaction,"
CB	1	Blood, September 15, 1991, Vol. 78, No. 6, pp. 1496-1502
	ER	Speidel et al., "Procoagulant Activity on Injured Arteries and Associated Thrombi Is Mediated
İ _	-''	Primarily by the Complex of Tissue Factor and Factor VIIa," Pathophysiology and Natural
CB		History, Coronary Artery Disease, January 1996, Vol. 7, No. 1, pp. 58-62
	ES	Stephens et al., "Production of Tissue Factor By Monocyte Porgenitor Cells," Thrombosis
CB	[5	Research, 1994, Vol. 76, No. 1, pp. 33-45
	ET	Sturm et al., "Immunohistological Detection of Tissue Factor in Normal and Abnormal Human
	= 1.	Mammary Glands Using Monoclonal Antibodies," Virchows Archiv A Pathological Anatomy
CB	1	
כיטן		and Histopathology, 1992, 421:79-86 Toomey et al., "Localization of the Human Tissue Factor Recognition Determinant of Human
	EU	Toomey et al., Cocalization of the Human Tissue Factor Recognition Determinant of Indiana
CB	1	Factor VIIa," The Journal of Biological Chemistry, October 15, 1991, Vol. 266, No. 29, pp.
		19198-19202
	EV	Tsao et al., "Monocytes Can Be Induced by Lipopolysaccharide-Triggered T Lymphocytes To
(B	1	Express Functional Factor VII/VIIa Protease Activity," J. Exp. Med., April 1934, Vol. 159, pp.
13	ļ	1042-1057
CB	EW	Tsuda et al., "Development of Antitissue Factor Antibodies in Patients After Liver Surgery,"
<u>U3</u>		Blood, Vol. 82, No. 1 July 1, 1993, pp. 96-102
	EX	Walsh et al., "Discordant Expression of Tissue Factor Antigen and Procoagulant Activity on
CB		Human Monocytes Activated with LPS and Low Dose Cycloheximide," Thrombosis and
<u>U15</u>		Haemostasis, F.K. Achattauer Verlagsgesellschaft mbH (Stuttgart), 1991, 66 (5), pp. 552-558
	EY	Warr et al., "Disseminated Intravascular Coagulation in Rabbits Induced by Administration of
١.	1	Endotoxin or Tissue Factor: Effect of Anti-Tissue Factor Antibodies and Measurement of
1/2		Plasma Extrinsic Pathway Inhibitor Activity," Blood, Vol. 75, No. 7, April 1, 1990, pp. 1481-
		1489
	EZ	Camerer et al., "Tissue Factor - And Factor X-Dependent Activation of Protease-Activated
LUB	<u></u>	Receptor 2 by Factor VIIa," PNAS, 97(10):5255-5260 (2000)
(B)	FA	Ruf et al., "Tissue Factor Signaling," Thrombosis and Haemostasis, 82(2):175-182 (1999)
	FB	Ollivier et al., "Tissue Factor-Dependent Vascular Endothelial Growth Factor Production by
CB	1	Human Fibroblasts in Response to Activated Factor VII," Blood, 91(8):2698-2703 (1998)
	FC	Wiiger et al., "Effects of Binding of Ligand (FVIIa) to Induced Tissue Factor in Human
CB	'	Endothelial Cells," Thrombosis Research, 98:311-321 (2000)
Ì	FD	Konigsberg et al., "The TF:VIIa Complex: Clinical Significance, Structure-Function
C	1	Relationships and Its Role in Signaling and Metastasis," Thrombosis Haemostasis, 86:757-771
1 UB		(2001)
<u> </u>	FE	Riewald et al., "Mechanistic Coupling of Protease Signaling and Initiation of Coagulation by
CB CB	l	Tissue Factor," PNAS, 98(14):7742-7747 (2001)
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	FF	Mueller et al. "Expression of Tissue Factor by Melanoma Cells Promote Efficient
163	l. ,	Hematogenous Metastasis," Proc. Nati. Acad. Sci. USA, 89:11832-11836 (1992)
	ــــــــــــــــــــــــــــــــــــــ	Tribinate general interestable, 1 ros. rati. rada. doi: 00/1, doi:1102.1102.1102.1102.

Evaminar	Date	1
Examiner 1	Date	8/./.~
Signature Christine Borglest	Considered	1 71107 1
Signature Copy Copy Copy Copy Copy Copy Copy Copy	Considered	

PTO/SB/08a/b (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	Substitute for form 1449A/B/PTO		Complete if Known		
	Subject to the territory of	•		Application Number	10/764,140-Conf. #6085
IN	IFORMATION	I DIS	SCLOSURE	Filing Date	January 22, 2004
S	TATEMENT E	3Y A	PPLICANT	First Named Inventor	Jin-An Jiao
				Art Unit	1647
	(Use as many she	ets as	necess ary)	Examiner Name	C. M. Borgeest
Sheet	8	of	9	Attorney Docket Number	TNA-00505

CA	FG	Poster Presentation Experimental Biology 2001, March 31-April 4, 2001, Orlando, Florida,						
CB	FH	Anti-Tissue Factor Antibodies Francis et al., "Effect of Antihemostatis Agents on Experimental Tumor Dissemination," Sem.						
CB	FI	in Thrombosis and Haemostasis, 28(1):29-38 (2002) Amirkhosravi et al., "The Suppression of Tumor Cell Procoagulant Activity, Experimental Metastasis and Primary Tumor Growth by Monoclonal Antibodies Against Tissue Factor," Suppl. to J. of Thrombosis and Haemostasis Abstract:OC1021 (2001)						
UB	CF	Wen, Jinghai et al. "Antibody-dependent cellular cytotoxicity and antibody dependent cellular phgocytosis of breast cancer cells mediated by anti-tissue factor monoclonal antibodies," FASEB Journal, 15(5):A1198 (2001) Annual Meeting of the Federation of American Societies for Experimental Biology on Experimental Biol; Orlando, Florida, March 31-April 4, 2001 Abstract						
CB	CG	Chothia et al., "The outline structure of the T-Cell αβ receptor," The EMBO Journal, 7(12):3745-3755 (1988)						
CB	Cl	Gascoigne et al., "Secretion of a chimeric T-cell receptor-immunoglobulin protein," Proc. Natl. Acad. Sci. USA, 84:2936-2940 (1987)						
CB	СК	George et al., "Current Methods in Sequence Comparison and Analysis," Marcomolecular Sequencing and Synthesis, Alan Riss, 127-149 (1988)						
B	CL	Gregoire et al., "Engineered secreted T-cell receptor αβ heterodimers," Proc. Natl. Acad. Sci. USA, 88:8077-8081 (1991)						
CB	СМ	Groves et al., "Production of an ovine monoclonal antibody to testosterone by an interspecies fusion," Hybriodoma, 6(1):71-76 (1987)						
OB	СО	Kappler et al., "Binding of a soluble αβ T-cell receptor to superantigen/major histocompatibility complex ligands," Proc. Natl. Acad. Sci. USA, 91:8462-8466 (1994)						
CB	СР	Kurucz et al., "A bacterially expressed single-chain Fv construct from the 2B4 T-cell receptor," Proc. Natl. Acad. Sci. USA, 90:3830-3834 (1993)						
CB	CQ	Lin et al., "Expression of T cell antigen receptor herodimers in a lipid-linked form," Science, 249:677-679 (1990)						
CB	CR	Mariuzza et al., "Secretion of a Homodimeric V₀Cκ T-cell Receptor-Immunoglobulin Chimeric						
GB.	cs	Protein," The Journal of Biological, 264(13):7310-7316 (1989) Morrison, SL, "In vitro antibodies: strategies for production and application," Ann. Rev. Immunol., 10:239-265 (1992)						
CB	СТ	Novotny et al., "A soluble, single-chain T-cell receptor fragment endowed with antigen- combining properties," Proc. Natl. Acad. Sci. USA, 88:8646-8650 (1991)						
CB	cu	Onda et al., "A phage display system for detection of T cell receptor-antigen interactions," Molecular Immunology, 32(17-18):1387-1397 (1995)						
CB	cv	Parmley et al., "Antibody-selectable filamentous fd phage vectors: affinity purification of target genes," Gene, 73:305-318 (1988)						
CB	cw	Presta et al., "Generation of a Humanized High Affinity Anti-Tissue Factor Antibody for Use as						
CB	СХ	a Novel Antithrombotic Therapeutic," Thromb Haemost 85:379-89 (2001) Ragni et al., "Monoclonal Antibody Against Tissue Factor Shortens Tissue Plasminogen Activator Lysis Time and Prevents Reocclusion in a Rabbit Model of Carotid Artery Thrombosis " Circulation, 93:1913, 1918 (1996)						
CB	CY	Thrombosis," Circulation, 93:1913-1918 (1996) Rao et al., "Purification and characterization of rabbit tissue factor," Thrombosis Research, 56:109-118 (1989)						
CA	CZ	Schlueter et al., "Specificity and binding properties of a single-chain T cell receptor," J. Mol. Biol., 256:859-869 (1996)						
14	DA	Smith et al., "Libraries of Peptides and Proteins Displayed on Filamentous Phage," Methods in Enzymology, 217:228-257 (1993)						
CB	DB	Soo Hoo et al., "Characterization of a single-chain T-cell receptor expressed in Escherichia coli," Proc. Natl. Acad. Sci. USA, 89:4759-4763 (1992)						
Examine Signature		hushing Bargeet Date Considered 3/1/2007						
3.9.10.011	~	VIVA-						

PTO/SB/08a/b (07-06)
Approved for use through 09/30/2006. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE espond to a collection of information unless it contains a valid OMB control number.

Substitu	Substitute for form 1449AB/PTO			Complete if Known		
	110 101111 144074	J J		Application Number	10/764,140-Conf. #6085	
INF	ORMATI	ON DI	SCLOSURE	Filing Date	January 22, 2004	
STA	ATEMEN	T BY	APPLICANT	First Named Inventor	Jin-An Jiao	
• • • • • • • • • • • • • • • • • • • •				Art Unit	1647	
	(Use as man	y sheets as	necessary)	Examiner Name	C. M. Borgeest	
Sheet	9	of	9	Attorney Docket Number	TNA-00505	

Cos		Ward, E. S., "Expression and Secretion of T-Cell Receptor Vα and Vβ Domains using Escherichia coli as a Host," Scand. J. Immunol., 34:215-220 (1991)	
	DE	Wulfing et al., "Correctly folded T-cell receptor fragments in the periplasm of Escherichia coli. Influence of folding catalysts," J. Mol. Biol., 242:655-669 (1994)	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{&#}x27;Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.